Frank P. Zemlan
Director Ejecutivo en Phase 2 Discovery, Inc. .
Cargos activos de Frank P. Zemlan
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Phase 2 Discovery, Inc.
 Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Director Ejecutivo | - | - |
Historial de carrera de Frank P. Zemlan
Antiguos cargos conocidos de Frank P. Zemlan.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - | - |
| GSK PLC | Corporate Officer/Principal | - | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Formación de Frank P. Zemlan.
| University of Pennsylvania | Doctorate Degree |
| Villanova University | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 6 |
| Reino Unido | 2 |
Operativa
| Corporate Officer/Principal | 3 |
| Chief Executive Officer | 1 |
| Graduate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| GSK PLC | Health Technology |
| Empresas privadas | 2 |
|---|---|
| Aventis, Inc. | |
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Health Technology |
- Bolsa de valores
- Insiders
- Frank P. Zemlan
- Experiencia
